Pathophysiology of the hepoxilins

Area of Science:

• Biochemistry
• Immunology
• Pharmacology

Background:

• Hepoxilins are increasingly recognized as novel inflammatory mediators.
• Evidence suggests their involvement in various inflammatory conditions and diseases.
• The hepoxilin pathway is present in multiple human tissues.

Purpose of the Study:

• To review the current evidence on hepoxilins as inflammatory mediators.
• To highlight the role of the hepoxilin pathway in health and disease.
• To explore the therapeutic potential of targeting the hepoxilin pathway.

Main Methods:

• In vitro studies on human neutrophils (calcium mobilization, chemotaxis).
• In vivo studies in animal models of inflammation, fibrosis, cancer, thrombosis, and diabetes.
• Analysis of genetic defects linked to hepoxilin deficiency (e.g., ichthyosis).
• Use of stable hepoxilin analogs to study pathway involvement.

Main Results:

• Hepoxilins mobilize intracellular calcium and stimulate neutrophil chemotaxis.
• The hepoxilin pathway is activated in inflammatory conditions like psoriasis and arthritis.
• Hepoxilins contribute to inflammatory hyperalgesia and allodynia.
• Hepoxilin pathway defects are linked to ichthyosis.
• Stable hepoxilin analogs show efficacy in models of lung fibrosis, cancer, thrombosis, and diabetes.

Conclusions:

• The hepoxilin pathway is a distinct and novel pathway involved in inflammation.
• Hepoxilin antagonists may offer a means to control acute inflammatory responses.
• Further research into hepoxilins holds significant therapeutic promise for inflammatory diseases.